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Background: Plasminogen activator inhibitor 1 (PAI-1) is a serpin that has a key
role in the control of fibrinolysis through proteinase inhibition. PAI-1 also has a
role in regulating cell adhesion processes relevant to tissue remodeling and
metastasis; this role is mediated by its binding to the adhesive glycoprotein
vitronectin rather than by proteinase inhibition. Active PAI-1 is metastable and
spontaneously transforms to an inactive latent conformation. Previous attempts
to crystallize the active conformation of PAI-1 have failed. 
Results: The crystal structure of a stable quadruple mutant of
PAI-1(Asn150→His, Lys154→Thr, Gln319→Leu, Met354→Ile) in its active
conformation has been solved at a nominal 3 Å resolution. In two of four
independent molecules within the crystal, the flexible reactive center loop is
unconstrained by crystal-packing contacts and is disordered. In the other two
molecules, the reactive center loop forms intimate loop–sheet interactions with
neighboring molecules, generating an infinite chain within the crystal. The
overall conformation resembles that seen for other active inhibitory serpins.
Conclusions: The structure clarifies the molecular basis of the stabilizing
mutations and the reduced affinity of PAI-1, on cleavage or in the latent form, for
vitronectin. The infinite chain of linked molecules also suggests a new
mechanism for the serpin polymerization associated with certain diseases. The
results support the concept that the reactive center loop of an active serpin is
flexible and has no defined conformation in the absence of intermolecular
contacts. The determination of the structure of the active form constitutes an
essential step for the rational design of PAI-1 inhibitors.
Introduction
Plasminogen activator inhibitor 1 (PAI-1), a member of
the serpin family of serine proteinase inhibitors, is the
main physiological inhibitor of tissue plasminogen acti-
vator (tPA) and urokinase plasminogen activator (uPA).
These serine proteinases convert plasminogen, an inactive
zymogen, to the active enzyme plasmin, which degrades
fibrin clots. Epidemiological studies have shown that ele-
vated circulating levels of PAI-1 are associated with coro-
nary heart disease and possibly atherosclerosis [1]. These
findings have led to considerable interest in the devel-
opment of drugs that specifically inhibit PAI-1. Such drugs
may have a wider clinical application as the fibrinolytic
system is also involved in ovulation, wound healing, angio-
genesis, tissue remodeling and neoplasia [2].
Serpins bind to their target enzymes through a highly
mobile peptide loop containing the reactive center or scis-
sile bond (denoted P1–P1′). The active form of a serpin is
apparently a metastable folding intermediate. Following
attack of the reactive center by a target enzyme, conforma-
tional strain is released and the serpin–proteinase complex
is trapped, probably at the acylenzyme step [3,4]. The
complex dissociates very slowly, yielding an irreversibly
inactivated cleaved serpin. The cleaved form has under-
gone a dramatic conformational change in which the N-ter-
minal end of the cleaved reactive center loop has been
inserted into the major β sheet (β sheet A), forming a new
β strand [5]. A similar loop insertion is believed to occur
in the formation of the inhibited complex [3]. PAI-1 is a
prototype among serpins due to its ability to convert spon-
taneously, without cleavage, to an inactive conformation
similar to the cleaved form; there is complete insertion of
the intact reactive center loop into β sheet A together with
release of the first strand of β sheet C [6]. This form of the
serpin is termed ‘latent’ as activity of the inhibitor can be
restored by denaturation and renaturation. Other serpins
can fold into a latent conformation [7] under mild thermal
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stress [8], and there is now evidence that latency has a
role in the senescence and pathology of antithrombin [9]. In
PAI-1, the spontaneous transition to latency may ensure
sufficient turnover to allow a rapid physiological response to
changing circumstances. In the circulation, most PAI-1 will
exist in a tight complex with the adhesive glycoprotein, vit-
ronectin. In such a complex in vitro, the lifetime of active
PAI-1 is doubled from about two hours to four hours under
physiological conditions [10].
Here, we describe the structure of a recombinant mutant
of PAI-1 that is more stable in its active form than wild-
type PAI-1 [11]. Attempts to crystallize active wild-type
PAI-1 have so far been unsuccessful. The structures of
latent PAI-1 [6] and two forms of cleaved PAI-1, by itself
[12] and with a bound reactive center loop peptide [13],
are already known. The addition of our structure of active
PAI-1 will make it possible to analyze the full extent of
the conformational transitions in PAI-1 without relying on
homology modeling. 
Results and discussion
Comparison with other active serpins
Since the determination of the first serpin structure, that
of cleaved α1-antitrypsin [5], many crystal structures have
been solved of serpins in various conformations. Intact,
active serpins have been the most difficult to crystallize,
but structures are now available for intact forms of α1-anti-
chymotrypsin [14], antithrombin [15,16] and α1-antitrypsin
[17]. In its general features (see Figure 1), as expected,
active PAI-1 resembles other active serpins.
The unusual flexibility of the reactive center loop is shown
by its markedly different conformations in the structures of
active serpins. In PAI-1, the reactive center loop also shows
evidence of mobility, and its conformation in the crystal
appears to be significantly influenced by packing contacts.
In two of the four independent PAI-1 molecules in the
crystal (molecules B and D, discussed below), there are
no packing contacts around the loop and it is disordered.
However, in the other two molecules the C-terminal portion
of the loop is tethered by crystal-packing contacts and is
probably induced to adopt an extended conformation. The
four molecules have been restrained to be almost identical
(root mean square [rms] deviations on all atoms of less than
0.3 Å), with only a few residues at the N termini and in the
reactive center loops being allowed to differ significantly.
As the A and C molecules are nearly identical (rms devia-
tion of 0.15 Å on all atoms), have the lowest overall temper-
ature factors and have complete reactive center loops, the A





















Schematic illustration of the three conformations of PAI-1. The major
β sheet (β sheet A) is highlighted in yellow, the reactive center loop is
in red and the gate region is shown in cyan. (a) The active
conformation of a stable mutant of PAI-1 (this work). (b) The latent
conformation of PAI-1 [6]. (c) The cleaved conformation of PAI-1 [12].
In both the latent and cleaved forms of PAI-1, the reactive center loop
is inserted into β sheet A to form a new β strand, 4A. (The figure was
prepared using the program MOLSCRIPT [40].)
molecule is used for discussion. The reactive center loop of
PAI-1 could not dock to a proteinase without altering the
conformation seen in the crystal, indicating that it must
be flexible. The only active serpin that has crystallized in
a conformation that could dock to a proteinase is α1-anti-
trypsin [17]. As seen in other active serpins, the reactive
center loop of PAI-1 appears poised to enter a gap between
β strands 3A and 5A.
A new mode of serpin polymerization
The four PAI-1 molecules in the P1 unit cell display
pseudo C2 symmetry. The two unique molecules in the
pseudo C2 cell (molecules A and B) form an improper
dimer, which is related to a second dimer (molecules C
and D) by a 21 screw axis. The interaction between this
pair of dimers is mediated primarily by an intimate contact
between the A and C molecules, in which the reactive
center loop of one molecule adds a β strand to the edge of
β sheet A of the other molecule. Repeated application of
the screw symmetry generates an infinite chain of A and C
molecules, shown in Figure 2.
This infinite chain of molecules may be relevant to the
formation of pathological polymers of serpin molecules
[18], as found in the liver disease associated with the Z
variant of α1-antitrypsin [19]. The mode of polymerization
differs from those proposed earlier, however, involving the
insertion of the reactive center loop of one molecule into
another molecule as an edge strand of β sheet C or the
central strand of β sheet A [18]. The interaction in the
stable mutant of PAI-1 is reversible, as the crystals can be
dissolved to give active PAI-1 (data not shown), but in other
serpins such polymers could be more stable. Furthermore,
the interaction illustrates the propensity of the reactive
center loop to enter into a β sheet, which is central to the
serpin mechanism of inhibition.
Factors influencing the latency transition
Although PAI-1 is unusual in the speed of its transition to
latency, the relevant structural differences from other
serpins are likely to be very subtle. Other inhibitory serpins
appear to exist in a metastable state, but have a larger
barrier to latency so that one must wait much longer or
subject them to harsher conditions. Nonetheless, an increase
of only 4 or 5 kcal/mol in the activation energy barrier to
latency would make PAI-1 stable for months under physi-
ological conditions. The quadruple mutant has a half-life
of 145 h at 37°C [11], so it is sufficiently stable at room








Infinite chain of PAI-1 molecules in the crystal lattice. (a) Molecules A
(red) and C (two copies in blue) are related by a pseudo-
crystallographic 21 screw axis. The reactive center loop of one
molecule forms a new strand ‘7A’ at the edge of β sheet A of the other
molecule. The β strands involved in the interaction are highlighted as
broad arrows. (The figure was prepared using the program
MOLSCRIPT [40].) (b) As a result of the interaction illustrated in (a),
density for the reactive center loop is reasonably clear in the A and C
molecules. Electron density, after averaging, is shown for the
interaction between β strand 6A of molecule A (residues A281–A284,
yellow) and the reactive center loop of molecule C (C341–C345, red).
For clarity, only electron density contours within 2.5 Å of an atom in the
figure are shown. (The figure was prepared using the program
XtalView [41].)
temperature to crystallize in the active form. This amounts,
however, to an increase of less than 3 kcal/mol in the energy
of the transition state to latency. 
As one would expect, all four mutations (see Figure 3) are
located in parts of the serpin molecule where movement
is known to occur during the transition from the active to
the latent form. Only one of the mutations (Met354→Ile)
reverses sequence differences between PAI-1 and the
majority of inhibitory serpins. Met354→Ile is in β strand 1C,
which forms the distal hinge of the reactive center loop
and also has to be unraveled in the latency transition. The
reverse mutation to methionine at the equivalent residue
(Val366→Met) in C1 inhibitor results in polymerization and
other evidence of reactive loop insertion [20]. In PAI-1, a
methionine may have evolved at this position to give a con-
formationally labile molecule compatible with its function,
whereas in C1 inhibitor, which has a higher concentration
and longer half-life in plasma, the same mutation has
adverse consequences [21].
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Figure 3
Mutations that increase stability in the
quadruple mutant of PAI-1. (a) Stereo
overview of the structure showing the
location of the four mutations with their
sidechains highlighted in red. (b) Close-up
stereoview of the three mutations associated
with a change in conformation that forms a
310 helix in the loop connecting helix F toβ strand 3A. The active form of the stable
PAI-1 mutant is shown in black, while the
residues for this loop from latent PAI-1 [6]
are shown in red. The latent structure has
been overlaid by superimposing residues
128–150 and residues 158–162. In other
serpins latency or cleavage has no significant
effect on the conformation of this loop. (The





























The other three mutations are close to one another, clus-
tered around the site where β sheet A opens to accept
the reactive center loop [21]. Interestingly, non-additive
effects on stability were found when various single, double
and triple combinations of the four mutations were eval-
uated [11]. The stabilizing effects of either Asn150→His
or Gln319→Leu are only fully achieved when combined
with Lys154→Thr; on its own, Asn150→His is actually
slightly destabilizing. The prediction that this reflected
complex structural interactions is now borne out by the
structure. The loop connecting helix F with β strand 3A
(which includes residues 150 and 154) contains a turn of 310
helix, unlike any other serpin of known structure including
latent and cleaved PAI-1. This conformation is only possi-
ble in the presence of Lys154→Thr, as the new threonine
sidechain is buried and hydrogen bonded (Figure 3b).
The other two mutations presumably also favor the 310
conformation, either through burial of hydrophobic surface
(Gln319→Leu) or through avoidance of steric conflict
(Asn150→His). The new conformation of the loop allows
hydrogen bonds to be formed to Glu283 in β strand 6A.
These hydrogen bonds would have to be broken in the
process of inserting the reactive center loop as a new strand
between β strands 3A and 5A and, together with increased
rigidity of the 310 helix, may account for a large part of the
increased barrier to latency.
When the structure of latent PAI-1 was determined, it was
found that the loop from His185 to Pro200 (β strands 3C to
4C, termed the ‘gate’) was poorly ordered [6]. It was sug-
gested that lack of order in this loop made it easier for the
C-terminal portion of the reactive center loop to move to
its final position in the latent form [22]. This argument is
intuitively attractive, and the gate may move more readily
in PAI-1 than in other serpins. However, our structure
does not provide experimental support, as the gate region
is well ordered. It was also suggested that an unusual posi-
tion for the C terminus caused the gate to be displaced
[22], but this must be a consequence of the latency transi-
tion as the C terminus of active PAI-1 occupies the same
position seen in other serpins.
Vitronectin binding
The adhesive glycoprotein vitronectin binds to the active
form of PAI-1, stabilizing it and altering its specificity.
This interaction is specific for active PAI-1, as the affinity
of vitronectin for latent, cleaved, proteinase-bound, and
other forms of PAI-1 with the reactive center loop inserted
into β sheet A is reduced by a factor of 100 or more [23].
The change in affinity may provide a mechanism for the
release of inactive PAI-1 from the extracellular matrix, fol-
lowed by clearance through uptake by the low density
lipoprotein (LDL) receptor related protein, LRP [24]. 
Recent results suggest that the binding of PAI-1 to vitro-
nectin competes with interactions mediating cell adhe-
sion events. Active PAI-1 has been found to compete
with αv-integrins [25] and the uPA receptor [26] for
binding to vitronectin. These results provide an explana-
tion for the association of high levels of PAI-1 with
increased risk of tumor metastasis [26] and also suggest a
means by which coagulation and tissue remodeling could
be coordinately regulated during wound healing [27].
Deficient PAI-1 expression in knockout mice has recently
been shown to prevent tumor invasion and vascularization
[28], supporting the proposed role of PAI-1 in metastasis.
Selection for random mutations of PAI-1 that reduce vit-
ronectin binding, but not inhibitor activity, has identi-
fied a patch of five residues near the strand 1 edge of
β sheet A [29]. The insertion of the reactive center loop
has been presumed to alter this surface, inhibiting binding.
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Figure 4
Conformational changes in the region of the
vitronectin-binding site that are caused by the
latency transition. Latent PAI-1 [6] (shown in
purple) has been overlaid on active PAI-1
(pink) by superimposing the large rigid
fragment defined by Stein and Chothia [42].
Ball-and-stick models indicate the location of
mutations that affect vitronectin binding
without affecting inhibitory activity [29]. Helix
E and β strand 1A have also been shown to
be important in vitronectin binding (see text
for discussion). (The figure was prepared




















Indeed, comparison of the active and latent structures
(Figure 4) reveals extensive rearrangements of the sec-
ondary structure elements in this region. Further struc-
tural studies will be required to determine the exact nature
of the binding surface.
Binding of drugs that modulate PAI-1 activity
Björquist and coworkers [30] present evidence that small
molecule PAI-1 inhibitors can bind in the vicinity of Arg76,
Arg115 and Arg118. The site corresponds essentially with
a pocket proposed as a good target for compounds that
inhibit  the polymerization of α1-antitrypsin [31]. This site
can be seen in Figure 4, above and behind helix E and
between β sheet A and helix D. The same region has been
implicated in the binding of heparin [18] and LRP [24],
suggesting that it is a general site for serpins to bind
ligands that influence, or are influenced by, the confor-
mational transitions.
Our results show the profound structural changes that
occur in this region on loop insertion (Figure 4). Confor-
mational changes are seen in this region in other serpins
and were thus expected to also occur in PAI-1 [30]. Drugs
could modulate PAI-1 activity by preventing, or accelerat-
ing, the latency transition or by slowing or eliminating
loop insertion on cleavage, thus converting PAI-1 into a
substrate. Because all such drugs would bind, at least ini-
tially, to the active form of PAI-1 our structure provides an
ideal starting point for structure-based drug design. 
Biological implications
Plasminogen activator inhibitor 1 (PAI-1), a serine pro-
teinase inhibitor from the serpin family, is being found to
have a key role in a growing number of medically rele-
vant pathways. Structural knowledge is essential for a
detailed understanding of these processes, because PAI-1
and other serpins are exceptional in the degree to which
conformational changes are required for function. Most
serpins exist in a metastable state and their mechanism of
proteinase inhibition exploits the energy released when
the cleaved serpin refolds into its lowest energy state. The
different serpin conformations can be distinguished by
receptors, with further consequences for function. 
PAI-1 is the physiological inhibitor of the fibrinolytic
pathway, which in turn limits the coagulation pathway
and hence prevents thrombosis. In keeping with this, the
diurnal rhythm in levels of PAI-1 may account for the
early morning occurrence of the majority of thromboses,
and the rebound in PAI-1 levels after fibrinolytic treat-
ment could contribute to the development of coronary
restenosis. PAI-1 is therefore a promising drug target for
the treatment of coronary heart disease. Useful drugs
should bind to the active conformation of PAI-1,
described here, but not necessarily to the latent or cleaved
conformations determined in previous crystal structures.
Intriguingly, PAI-1 is now being identified as a key
player in the link between coagulation and the cell adhe-
sion pathways involved in tissue remodeling and meta-
stasis. Active PAI-1 (but not its latent or cleaved forms)
binds tightly to the adhesive glycoprotein vitronectin in
the extracellular matrix. This binding localizes active
PAI-1 at the site of its action in the fibrinolytic pathway,
as well as doubling its half-life. It is now apparent,
however, that, as a vitronectin ligand, active PAI-1
competes with αv-integrins and the receptor for uroki-
nase plasminogen activator. This potential to modulate
cell adhesion to the tissue matrix opens further possibili-
ties for rational drug design.
Materials and methods
Protein expression and purification
Mutant protein was expressed and purified as before [11], or was
obtained from Molecular Innovations. Purified protein was concen-
trated to 5 mg/ml in 10 mM cacodylate pH 6.8, 0.25 M NaCl and
1 mM EDTA. 
Crystallization
Crystals were produced by the hanging-drop method, equilibrating
against 27–32% saturated ammonium sulfate, 0.25 M NaCl and 10 mM
cacodylate pH 6.8 at room temperature. 
Data collection
Data were collected from a single crystal on a Siemens multiwire area
detector mounted on a Siemens rotating anode. Crystals were cry-
oprotected by transfer to 25% glycerol solutions and were cooled to
111K with an Oxford cryostream. The data were reduced using the
program Xengen 2.0 [32] and programs from the Biomol package (Uni-
versity of Groningen). 
Molecular replacement
Self-rotation and cross-rotation functions were computed with AMoRe
[33]. Self-rotation functions indicated twofold symmetry parallel to the
a axis. Cross-rotation functions, computed using latent PAI-1 [6] as a
search model, showed four peaks. The AMoRe translation function was
used to find solutions for this set of orientations, consistent with one
improper dimer (A–B) related to another (C–D) by a twofold screw
operation. (Molecule A is related to B by a 64° rotation and a 27 Å
screw translation.) Rigid-body refinement was conducted with the
program X-PLOR [34] using data from 10 to 5 Å resolution and allow-
ing residues 90–175 (β strands 1A, 2A and 3A and associated loops
and helices) to move as a rigid fragment relative to the rest of the mol-
ecule. This allowed β strand 3A to move into the position beside
β strand 5A that was previously occupied by β strand 4A (the reactive
center loop). 
Refinement
Refinement was carried out initially with X-PLOR and later with CNS
[35], using the maximum-likelihood refinement target MLI (MLF2 in
[36]) and a correction for bulk solvent [37]. Rounds of refinement
were alternated with rebuilding in the program O [38], inspecting the
model in electron-density maps that had been averaged and solvent-
flattened with the DEMON package [39]. Strict noncrystallographic
symmetry (NCS) was maintained until it became obvious that the
reactive center loops in molecules A and C differed from those in B
and D, after which strong NCS restraints were imposed. Thermal
motion parameters (B values) were refined only for groups of main-
chain and sidechain atoms. The final model includes residues 7 to
379 in molecules A and C, and residues 7 to 332 (P15) and 348
(P2′) to 379 in molecules B and D. Statistics for the final model are
summarized in Table 1.
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Accession numbers
The atomic coordinates have been deposited with the Brookhaven
Protein Data Bank with accession code 1b3k.
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